Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Long-acting reliever/preventer inhalers.

  • Comment

VOL: 101, ISSUE: 25, PAGE NO: 31

Generic/proprietary names

- Seretide: Evohaler 50; 125; 250.

- Seretide: Accuhaler 100; 250; 500.

- Symbicort Turbohaler 100/6; 200/6 400/12.

Action

- This inhaler contains two active ingredients: inhaled corticosteroids, either fluticasone propionate or budesonide; and a long-acting beta2 agonist, which is either salmeterol or formoterol fumarate.

- The inhaled corticosteroids act to decrease inflammation in airways.

- The long-acting beta2 agonist causes brochodilation.

Classification

- Respiratory system drugs.

Indications

- Used in the treatment of asthma and chronic obstructive pulmonary disease.

Contraindications

- Known sensitivity or allergy to any ingredient.

Cautions

- Active tuberculosis.

- Hyperthyroidism.

- Cardiovascular disease.

- Arrhythmias.

- Diabetes.

Side-effects

- Hoarseness.

- Candidiasis of mouth or throat.

- Tremor.

- Palpitations.

- Headache.

- Muscle cramps.

- Tachycardia.

- Sleep disturbance.

- Cataracts.

- High doses have the potential to cause adrenal suppression.

- Small increased risk of glaucoma with prolonged use at high dosage.

Interactions

- Potential for hypokalaemia can be increased by theophylline corticosteroids and diuretics.

Administration

- Metered dose aerosol inhaler.

- Metered dose dry powder inhaler.

Nursing considerations

- The use of long-acting reliever/preventer inhalers should be informed by evidence-based guidelines such as those produced by SIGN (2004) and NICE (2004).

- Assess respiratory function.

- Assess ability to use the inhaler device and reassess technique at regular appointments, giving coaching where appropriate.

- No significant growth retardation has been noted. However, it is recommended that the height of all children on regular therapy is monitored.

Patient teaching

- Ensure the patient can self-manage appropriately.

- Advise patients not to stop this medication without speaking to the prescribing health care professional.

- Give smoking cessation advice if appropriate.

- Ensure patients know never to use this medication to treat an acute attack. They should have an appropriate short-acting reliever inhaler for this purpose.

- Give appropriate advice about maintaining the device.

Nurses should refer to manufacturer’s summary of product characteristics and to appropriate local guidelines

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.